Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Baxter
AstraZeneca
McKesson
McKinsey

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SEMAGLUTIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Semaglutide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00696657 A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide Completed Novo Nordisk A/S Phase 2 2008-06-01 This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.
NCT00813020 A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects Completed Novo Nordisk A/S Phase 1 2009-01-01 This trial is conducted in Europe. The aim of this clinical trial is to investigate whether differences exist between three different concentrations of the drug, NN9535, administered in healthy male subjects in equal doses.
NCT00833716 Effect of Renal Impairment on the Pharmacokinetics of NN9535 Completed Novo Nordisk A/S Phase 1 2009-02-01 This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.
NCT00851773 Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects Completed Novo Nordisk A/S Phase 1 2009-02-01 This trial is conducted in Europe. The aim of this clinical trial is to assess and compare the safety and tolerability, as assessed by adverse events after multiple subcutaneous doses of NN9535 in healthy male Japanese and Caucasian subjects.
NCT01272973 Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects Completed Novo Nordisk A/S Phase 1 2011-01-01 This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of NN9924 in healthy male subjects
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Semaglutide

Condition Name

Condition Name for Semaglutide
Intervention Trials
Diabetes Mellitus, Type 2 61
Diabetes 61
Healthy 24
Obesity 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Semaglutide
Intervention Trials
Diabetes Mellitus 66
Diabetes Mellitus, Type 2 64
Overweight 14
Obesity 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Semaglutide

Trials by Country

Trials by Country for Semaglutide
Location Trials
United States 617
India 91
Germany 45
Mexico 44
Canada 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Semaglutide
Location Trials
California 31
Texas 30
Florida 28
Georgia 25
North Carolina 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Semaglutide

Clinical Trial Phase

Clinical Trial Phase for Semaglutide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 37
Phase 2/Phase 3 2
[disabled in preview] 58
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Semaglutide
Clinical Trial Phase Trials
Completed 40
Not yet recruiting 30
Recruiting 27
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Semaglutide

Sponsor Name

Sponsor Name for Semaglutide
Sponsor Trials
Novo Nordisk A/S 94
Eli Lilly and Company 3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Semaglutide
Sponsor Trials
Industry 98
Other 6
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Harvard Business School
Baxter
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.